News
- Author:
- Will Pass
Publish date: November 8, 2019
BOSTON – Interim results of the open-label LIFT trial show positive results after 6 months of therapy.
News
- Author:
- Will Pass
Publish date: November 8, 2019
BOSTON – In a phase 1b trial, treatment with tolerable doses of the bispecific antibody reduced hepatic fat fraction by a mean of 38%.
News
- Author:
- Will Pass
Publish date: November 6, 2019
Experimental models have shown that ammonia exposure with astrocyte swelling and brain edema are potentiated by proinflammatory cytokines.
News
- Author:
- Will Pass
Publish date: October 23, 2019
After a median follow-up of 20.7 months, the addition of ramucirumab was associated with a significantly better median PFS, at 19.4 months, compare...
News
- Author:
- Will Pass
Publish date: October 23, 2019
The blood-based triage test, which relies upon four host proteins and one TB antigen, is another step closer toward standards proposed by the WHO.<...
News
- Author:
- Will Pass
Publish date: October 22, 2019
The benefit of trastuzumab was greater among patients with HR+ disease than those with HR– disease until the 5-year timepoint, after which HR statu...
News
- Author:
- Will Pass
Publish date: October 21, 2019
The guideline provides recommendations for adult patients with either immune or hereditary TTP, from acute events through remission, including diag...
News
- Author:
- Will Pass
Publish date: October 17, 2019
Worldwide, more than 60% of countries had an inadequate supply of blood to meet the demand for transfusion.
News
- Author:
- Will Pass
Publish date: October 15, 2019
Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists.
News
- Author:
- Will Pass
Publish date: October 10, 2019
Dr. J. Michael Soucie of the Centers for Disease Control and Prevention said having more accurate prevalence data will help improve access to care ...
News
- Author:
- Will Pass
Publish date: October 4, 2019
Prospective cohort study results help to resolve findings from previous studies that left unclear results about NSAIDs’ hypertensive effects on pat...
News
- Author:
- Will Pass
Publish date: October 4, 2019
Modeling suggests high-risk multigene testing for all breast cancer patients might be cost-effective, but critics suggest “true costs are hidden wi...
News
- Author:
- Will Pass
Publish date: October 2, 2019
Perturbations to the CD44v9-xCT system often result in redox imbalance, and ultimately gastric metaplasia.
News
- Author:
- Will Pass
Publish date: October 1, 2019
Endoscopic submucosal dissection (ESD) is a viable treatment option for patients with submucosal (T1b) esophageal cancer who have a low risk of lym...
News
- Author:
- Will Pass
Publish date: September 24, 2019
Adding an antiandrogen may increase the risk of other-cause mortality by twofold or more for men with prostate cancer who have a low PSA level prio...
